Companies / Switzerland
Sandoz Plans Biosimilar Strategy
May 2006 | Product LaunchSandoz - the generics division of Switzerland's Novartis - is planning a significant assault on the biotechnology industry by launching five biosimilars in the near
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
